Revenue was $83.5 million versus $8.2 million, with an adjustment tied to updated costs; IBD dose-range studies are expected to begin in Q4 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results